Dr. Ravi Salgia

About Ravi Salgia

Accolades

• 

  Pleural and Lung Cancer

• 

  Excellence in Research

• 

  Team Leader

• 

  30+ Years of Experience

• 

  Board Certified in Medical Oncology

• 

  Board Certified in Internal Medicine

Get to Know Dr. Ravi Salgia

Medical oncologist Dr. Ravi Salgia specializes in the treatment of lung cancer and pleural mesothelioma, focusing his research on the molecular mutations in thoracic malignancies.

In his role at City of Hope Comprehensive Cancer Center, he works to create novel medicines designed to treat patients more effectively. He also treats thymic malignancies and bronchial carcinoids.

Salgia has earned a reputation as both an innovator and a healer. He joined City of Hope in 2016 after 12 years at the University of Chicago Comprehensive Cancer Center, where he directed the thoracic oncology program and helped pioneer the growth of immunotherapy.

He has been instrumental in expanding City of Hope’s clinical trials program. He also serves on various panels for the National Cancer Institute, including the Thoracic Malignancy Steering Committee.

Salgia’s advanced research regularly receives funding from the National Institutes of Health.

Specialties of Dr. Ravi Salgia

• Lung cancer

• Pleural mesothelioma

• Immunotherapy

• Research

• Targeted therapies

• Drug development

Dr. Ravi Salgia’s Experience and Medical Education

• City of Hope Comprehensive Cancer Center

• Chicago Comprehensive Cancer Center

• Dana-Farber Cancer Institute, Brigham and Women’s Hospital (Fellowships)

• Johns Hopkins Hospital (Residency)

• Loyola University School of Medicine (M.D., Ph.D.)

Awards and Certifications

• American Board of Internal Medicine

• Top Doctors in America

• Sun Pharma Research Awards, Clinical Research

• Chicago magazine’s Top Doctors

• IACA Award for Outstanding Contributions to Oncology

• Los Angeles Business Journal, Top Doctor

Publications of Dr. Ravi Salgia

• Rajurkar, S. et al. (2020, June 15). Non-Small Cell Lung Cancer from Genomics to Therapeutics: A Framework for Community Practice Integration to Arrive at Personalized Therapy Strategies. Journal of Clinical Medicine.

• Salgia, R. et al. (2020, July). The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping. Cancer Treatment Reviews.

• Gong, J. & Salgia, R. (2018, June). Managing Patients With Relapsed Small-Cell Lung Cancer. Journal of Oncology Practice.

• Salgia, R. et al. (2018, May 25). Modeling small cell lung cancer (SCLC) biology through deterministic and stochastic mathematical models. Oncotarget.

Top